These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22433538)

  • 1. [Denosumab--treatment of osteoporosis and cancer].
    Vestergaard P
    Ugeskr Laeger; 2012 Mar; 174(12):781. PubMed ID: 22433538
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
    Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
    Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: a novel antiresorptive drug for osteoporosis.
    Suresh E; Abrahamsen B
    Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for the treatment of osteoporosis and cancer-related conditions.
    Lewiecki EM; Bilezikian JP
    Clin Pharmacol Ther; 2012 Jan; 91(1):123-33. PubMed ID: 22158568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
    Vignot S; Khayat D
    J Clin Oncol; 2009 Apr; 27(10):1534-6. PubMed ID: 19237628
    [No Abstract]   [Full Text] [Related]  

  • 10. [Present and future of the treatment of osteoporosis with monoclonal antibodies].
    Fiter Aresté J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S8-12. PubMed ID: 21924213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients.
    Yee AJ; Raje NS
    Clin Interv Aging; 2012; 7():331-8. PubMed ID: 22977302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
    Ulas A; Bulent Akinci M; Silay K; Sendur MA; Sener Dede D; Yalcin B
    J BUON; 2015; 20(2):666-7. PubMed ID: 26011370
    [No Abstract]   [Full Text] [Related]  

  • 16. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab is an option for treatment of osteoporosis.
    Simonelli C
    Am Fam Physician; 2012 Dec; 86(11):992; author reply 994. PubMed ID: 23198660
    [No Abstract]   [Full Text] [Related]  

  • 18. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl.
    Karras NA; Polgreen LE; Ogilvie C; Manivel JC; Skubitz KM; Lipsitz E
    J Clin Oncol; 2013 Apr; 31(12):e200-2. PubMed ID: 23509309
    [No Abstract]   [Full Text] [Related]  

  • 19. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab, a rank ligand inhibitor for prevention of skeletal-related events due to bone metastases from solid tumors in adults.
    Wilkes GM
    Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):46-7. PubMed ID: 25391208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.